ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05047523
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05019521
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
A Study of the Cardiac Effects of Danicopan in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Moxifloxacin-matching PlaceboDrug: Danicopan-matching placebo
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT05016206
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04999020
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04982289
- Locations
- 🇺🇸
Clinical Study Site, Phoenix, Arizona, United States
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04980248
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Study in Adult and Pediatric Patients With HSCT-TMA
Withdrawn
- Conditions
- Stem Cell Transplant ComplicationsThrombotic Microangiopathies
- Interventions
- Other: No intervention
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04970004
- Locations
- 🇺🇸
Clinical Trial Site, Salt Lake City, Utah, United States
Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04958135
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04956276
- Locations
- 🇺🇸
Clinical Study Site, Riverside, California, United States
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04952545
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath